A Phase I/IIa Study of the Whole-Cell Vaccine BriaVax™ in Metastatic or Locally Recurrent Breast Cancer Patients

Trial Profile

A Phase I/IIa Study of the Whole-Cell Vaccine BriaVax™ in Metastatic or Locally Recurrent Breast Cancer Patients

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Aug 2017

At a glance

  • Drugs SV-BR-1-GM breast cancer vaccine BriaCell Therapeutics (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors BriaCell Therapeutics Corp
  • Most Recent Events

    • 31 Jul 2017 According to a BriaCell Therapeutics media release, this trial has been opened at a second clinical site, Florida Cancer Care in Plantation, FL, and Dr. Elizabeth Tan-Chiu will be the principal investigator at this site.
    • 19 Jul 2017 According to a BriaCell Therapeutics media release, the third patient has been enrolled in this trial. The company is on track to complete the enrollment of the first 10 patients by the end of Sept 2017. Interim data in these patients should be available in 1Q2018.
    • 01 Jun 2017 According to a BriaCell Therapeutics media release, a second patient has been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top